Seeking Alpha

Repros Therapeutics (RPRX +5.7%) will submit a design for a Phase II trial of an oral version of...

Repros Therapeutics (RPRX +5.7%) will submit a design for a Phase II trial of an oral version of its tumor drug Proellex in the next few days as the company attempts to persuade the FDA to lift a suspension on testing of the treatment. The FDA put a study of Proellex on hold in 2009 due to liver toxicity issues.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|